<DOC>
	<DOCNO>NCT02225392</DOCNO>
	<brief_summary>Approximately 5 % asthma patient suffer severe asthma characterize frequent asthma exacerbation result significant morbidity excessive utilisation health care resource . Therefore , strong need improve therapeutic strategy patient . Insight pathogenesis molecular pathway active severe asthma crucial reach goal . Bronchial Thermoplasty ( BT ) novel , innovative device-based treatment severe asthma base local , radiofrequent energy delivery large airway bronchoscopy . Hypothesis : BT-induced clinical improvement severe asthma consequence reduction airway smooth muscle ( ASM ) mass ( contractile/immunomodulatory ) function , inflammation , neural innervation and/or vascular integrity result alter airway remodelling . BT target identification severe asthma phenotyping critical improve patient selection BT fundamental discover novel , specific signal pathway active severe asthma .</brief_summary>
	<brief_title>Unravelling Targets Therapy Bronchial Thermoplasty Severe Asthma</brief_title>
	<detailed_description>This study two-fold purpose : 1. unravel target BT severe asthma ( work ? ) fundamental well patient selection ( benefit ? ) improvement BT technology novel asthma therapy development ( treat well ? ) . These objective achieve link patient-reported outcome airway structure/function , principal aim study propose . 2. investigate clinical outcome analysis</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Males females age 18 great 65 less 2 . The diagnosis asthma confirm least one follow assess least past 5 year study : Reversibility β2agonists ≥12 % predict ≥200ml 400μg inhaled salbutamol equivalent Bronchial hyperresponsiveness methacholine histamine Peakflow variability &gt; 20 % period 14 day Fall FEV1 &gt; 12 % &gt; 200ml tapering treatment ( ICS , oral steroid , LABA and/or LTRA ) . 3 . Subject take regular maintenance medication ( GINA step 45 ) past 6 month include : Inhaled corticosteroid dosage ≥500μg fluticasone equivalent per day AND Long act ß2agonist dosage ≥100μg per day salmeterol dose aerosol equivalent ) . 4 . Per protocol bronchial hyperresponsiveness methacholine ( PC20 &lt; 4 mg/ml ) 5 . Other asthma medication acceptable ( Leukotriene modifier , Theophylline , Omalizumab treatment ( discontinuation least 6 month ) Systemic corticosteroid use ( ≤20mg/day prednisone equivalent ) ) 6 . Prebronchodilator FEV1 ≥50 % predict ( stabilized ICS/LABA ) postbronchodilator FEV1 ≥60 % 7 . ACQ &gt; 1,5 2 week 8 . Nonsmoker 1 year ( former smoker ≤15 pack year ) 9 . Ability undergo bronchoscopy BT opinion investigator . 10 . Ability willingness provide inform consent . 11 . For woman childbearing potential : non pregnant , nonlactating , agree practice adequate birth control method duration study . 1 . Asthma exacerbation prior 4 week . 2 . Subject 5 hospitalization exacerbation asthma previous year 1 ICU admission mechanical endotracheal intubation asthma previous year . 3 . Respiratory tract infection within past 4 week 4 . Subject know sensitivity medication require perform bronchoscopy 5 . Subject use immunosuppressant therapy oral steroid therapy 6 . Subject anticoagulant medication include antiplatelet agent . 7 . Subject bleed diathesis , platelet dysfunction , thrombocytopenia platelet count le 125,000/mm2 know coagulopathy ( INR &gt; 1.5 ) . 8 . Subject respiratory disease include interstitial lung disease , emphysema , cystic fibrosis , mechanical upper airway obstruction , ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis ( total IgE &gt; 1000 Units/mL positive specific IgE aspergillus evidence central bronchiectasis ) . 9 . Subject segmental atelectasis , lobar consolidation , significant unstable pulmonary infiltrate , pneumothorax , confirm xray . Bronchiectasis HRCTof chest , centrally peripherally exclude . 10 . Subject clinically significant cardiovascular disease , include myocardial infarction , angina , cardiac dysrhythmia , conduction defect , cardiomyopathy , aortic aneurysm , stroke discretion investigator 11 . Subject uncontrolled hypertension ( &gt; 200mmHg systolic &gt; 100mmHg diastolic pressure ) . 12 . Subject use internal external pacemaker cardiac defibrillator . 13 . Other chronic disease opinion investigator would prevent participation trial put participant risk participation , e.g . liver , kidney , nervous system 14 . Current smoker , history cigarette smoke &gt; 15 pack year total 15 . Use investigative drug intervention trial 4 month prior enrolment duration study 16 . Any condition compliance issue opinion investigator might interfere participation inthe study 17 . BMI &gt; 35 18 . Prebronchodilator FEV1 &lt; 1.2L 19 . Extreme cough</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bronchial thermoplasty</keyword>
	<keyword>Severe asthma</keyword>
</DOC>